

15 Aug 2022 | Analysis

Inflation, Supply Chain Headaches And Staffing Shortages: CEOs Talk About 'Big Picture' Challenges

by **Reed Miller**

Although procedure volumes have mostly recovered from the shock of COVID-19 two years ago, the effects of the pandemic on the medtech sector and the economy overall will be felt for years to come. In recent analyst and sales and earnings presentations, CEOs of major medtech companies faced questions about how their company is handling these major "macro" issues.

During their recent presentations for analysts and investors, the CEOs of [Abbott](#), [Johnson & Johnson](#), [Medtronic](#), [Edwards Lifesciences](#), [Stryker](#) and [Zimmer Biomet](#) each discussed the major "headwinds" their companies are facing at this unprecedented moment in history. *In Vivo* compiled some of the highlights.



Robert Ford
CEO of Abbott

”

If you look at a lot of the financial and consumer indicators, retail, housing, auto, etc, those tend to point towards an increased risk here of recession.

So, what I would say is, historically in the macro environment, health care has proven to be pretty resilient, and whether it's the durability of these essential procedures and products (and you can only defer them somewhat), a large portion of the health care spend is government funded, and we've got a diversified model that's proved itself to be very resilient in this kind of environment.

20 July 2022

Read more about Abbott's ongoing [*investments in health diversity and inclusion*](#).



Joaquin
CEO of Johnson & Johnson